News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,425 Results
Type
Article (8232)
Company Profile (139)
Press Release (476054)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (167063)
Career Advice (307)
Deals (25790)
Drug Delivery (7)
Drug Development (53157)
Employer Resources (14)
FDA (9791)
Job Trends (8596)
News (238807)
Policy (17969)
Tag
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (513)
Accelerated approval (21)
ADA (18)
Adcomms (1)
Allergies (94)
Alliances (33231)
ALS (105)
Alzheimer's disease (966)
Antibody-drug conjugate (ADC) (255)
Approvals (10368)
Artificial intelligence (310)
ASCO (160)
Autoimmune disease (195)
Automation (29)
Bankruptcy (262)
Best Places to Work (6971)
BIO (36)
BIOSECURE Act (1)
Biosimilars (103)
Biotechnology (88)
Bladder cancer (132)
Brain cancer (28)
Breast cancer (500)
Cancer (3570)
Cardiovascular disease (215)
Career advice (246)
Career pathing (1)
CAR-T (170)
Celiac Disease (1)
Cell therapy (487)
Cervical cancer (34)
Clinical research (47939)
Collaboration (1206)
Compensation (1409)
Complete response letters (33)
COVID-19 (763)
CRISPR (63)
C-suite (707)
Cystic fibrosis (84)
Data (5524)
Denatured (4)
Depression (101)
Dermatology (59)
Diabetes (334)
Diagnostics (4147)
Digital health (36)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (144)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (171)
Earnings (73048)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87631)
Executive appointments (686)
FDA (12320)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (17)
Frontotemporal dementia (23)
Funding (896)
Gene editing (125)
Generative AI (10)
Gene therapy (315)
GLP-1 (286)
Government (943)
Grass and pollen (2)
Guidances (278)
Healthcare (9345)
Hematology (109)
HIV (49)
Huntington's disease (23)
IgA nephropathy (60)
Immunology and inflammation (95)
Immuno-oncology (54)
Indications (149)
Infectious disease (948)
Inflammatory bowel disease (125)
Inflation Reduction Act (4)
Influenza (83)
Intellectual property (246)
Interviews (41)
IPO (12396)
IRA (2)
Job creations (1972)
Job search strategy (236)
JPM (1)
Kidney cancer (14)
Layoffs (61)
Legal (5198)
Liver cancer (43)
Longevity (15)
Lung cancer (488)
Lymphoma (240)
Machine learning (27)
Management (3)
Manufacturing (515)
Marketing (6)
MASH (115)
Medical device (8633)
Medtech (8751)
Mergers & acquisitions (14378)
Metabolic disorders (687)
mRNA (51)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (218)
Neuropsychiatric disorders (38)
Neuroscience (1797)
NextGen: Class of 2026 (3178)
Non-profit (849)
Obesity (220)
Opinion (11)
Ovarian cancer (157)
Pain (168)
Pancreatic cancer (190)
Parkinson's disease (208)
Partnered (11)
Patents (456)
Patient recruitment (475)
Peanut (31)
People (41202)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15533)
Phase 2 (21424)
Phase 3 (14410)
Pipeline (6639)
Policy (18)
Postmarket research (1573)
Preclinical (6577)
Press Release (34)
Prostate cancer (188)
Psychedelics (7)
Radiopharmaceuticals (188)
Rare diseases (565)
Real estate (3028)
Recruiting (6)
Regulatory (14717)
Reports (16)
Research institute (596)
Resumes & cover letters (45)
Rett syndrome (39)
RNA editing (5)
RSV (47)
Schizophrenia (97)
Series A (148)
Series B (117)
Service/supplier (4)
Sickle cell disease (68)
Spinal muscular atrophy (87)
Sponsored (6)
Startups (2028)
Stomach cancer (3)
Supply chain (47)
Vaccines (313)
Venture capital (17)
Weight loss (69)
Women's health (74)
Date
Today (74)
Last 7 days (264)
Last 30 days (1123)
Last 365 days (19233)
2026 (10657)
2025 (19349)
2024 (23068)
2023 (26624)
2022 (34685)
2021 (37300)
2020 (33561)
2019 (23363)
2018 (17531)
2017 (18840)
2016 (17989)
2015 (24334)
2014 (21714)
2013 (18186)
2012 (20258)
2011 (20493)
2010 (20383)
Location
Africa (229)
Alabama (68)
Alaska (2)
Arizona (291)
Arkansas (11)
Asia (18024)
Australia (2147)
California (11541)
Canada (3041)
China (512)
Colorado (464)
Connecticut (389)
Delaware (206)
Europe (24930)
Florida (1712)
Georgia (364)
Hawaii (2)
Idaho (46)
Illinois (674)
India (41)
Indiana (308)
Iowa (13)
Japan (386)
Kansas (98)
Kentucky (30)
Louisiana (24)
Maine (25)
Maryland (1153)
Massachusetts (7586)
Michigan (299)
Minnesota (535)
Mississippi (4)
Missouri (77)
Montana (20)
Nebraska (11)
Nevada (112)
New Hampshire (60)
New Jersey (2533)
New Mexico (12)
New York (2738)
North Carolina (1224)
North Dakota (4)
Northern California (5762)
Ohio (265)
Oklahoma (14)
Oregon (14)
Pennsylvania (2190)
Puerto Rico (20)
Rhode Island (29)
South America (408)
South Carolina (75)
South Dakota (1)
Southern California (4770)
Tennessee (113)
Texas (1860)
United States (37489)
Utah (343)
Vermont (1)
Virginia (144)
Washington D.C. (38)
Washington State (896)
West Virginia (1)
Wisconsin (72)
484,425 Results for "progenity inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
January 8, 2026
·
4 min read
Business
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”)(Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a definitive agreement with ProGen Co., Ltd.
June 24, 2024
·
7 min read
Press Releases
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery
July 14, 2025
·
1 min read
Press Releases
Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
July 15, 2026
·
6 min read
Business
Progenity to Report First Quarter Financial Results and Provide Corporate Update as Biora Therapeutics, Inc.
Progenity, Inc. (Nasdaq: PROG) today announced that it will report first quarter ended March 31, 2022 financial results on Tuesday, May 10, 2022 after the close of financial markets.
May 3, 2022
·
1 min read
Press Releases
Progentec Diagnostics Advances Ability to Determine Lupus Risk with New Research and OCAST Grant
April 10, 2026
·
2 min read
Biotech Beach
Progenity Announces New Patent for Single-Molecule Detection Technology
Progenity, Inc. today announced a new patent related to its single-molecule detection platform under development.
December 2, 2021
·
4 min read
Biotech Beach
Progenity Announces Successful Transfer of Liquid Biopsy Technologies
Progenity, Inc. announced it has completed the divesture of a collection of novel, discovery-stage biochemical and bioinformatics technologies, including single-molecule detection, which are designed to enable next-generation rapid, low-cost assessment of biomolecules via liquid biopsy.
May 5, 2022
·
5 min read
Biotech Beach
Progenity Announces Two Poster Presentations at Controlled Release Society 2022
Progenity, Inc. today announced the acceptance of two abstracts presenting preclinical data on its systemic therapeutics delivery system for presentation at the Controlled Release Society (CRS) 2022 Annual Meeting.
April 6, 2022
·
1 min read
Biotech Beach
Progenity to Become Biora Therapeutics as it Completes Transformation
Progenity, Inc. announced that it will change its name to Biora Therapeutics, Inc. during the second quarter of 2022, to better reflect the company’s focus on developing its pipeline for targeted and systemic oral delivery of biotherapeutics.
April 12, 2022
·
1 min read
1 of 48,443
Next
